Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABOSTO:ONCOZ +4.03%26 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:ONCOZ with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, OncoZenge AB ranks worse than 77.37% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoZenge AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-10.85 Mil. OncoZenge AB's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. Therefore, OncoZenge AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for OncoZenge AB's FCF Margin % or its related term are showing as below:
OSTO:ONCOZ'
s FCF Margin % Range Over the Past 10 Years
Min: -824.92 Med: -490.13 Max: -490.13
Current: -824.92
During the past 6 years, the highest FCF Margin % of OncoZenge AB was -490.13%. The lowest was -824.92%. And the median was -490.13%.
OSTO:ONCOZ's FCF Margin % is ranked worse than 77.37% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs OSTO:ONCOZ: -824.92
OncoZenge AB FCF Margin % Related Terms
OncoZenge AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for OncoZenge AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ONCOZ vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, OncoZenge AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoZenge AB (OSTO:ONCOZ) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #735 out of 950 companies in the Biotechnology industry, placing it in the top 77.4%.
Is OncoZenge AB's FCF Margin % too high?
OncoZenge AB's current FCF Margin % is 0.00%. Based on the distribution chart, OncoZenge AB ranks #735 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #735 out of 950 companies for FCF Margin %. This places OncoZenge AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (OSTO:ONCOZ) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For OncoZenge AB (OSTO:ONCOZ), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score
Get the complete analysis for OSTO:ONCOZ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ONCOZ has been successfully added to your 
